TELA Bio, Inc.

As of September 10, 2025, TELA Bio, Inc. has shifted to a bearish trend, indicated by negative signals from MACD, moving averages, and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -47.35%.

As of June 6, 2025, TELA Bio, Inc. shows a mildly bearish trend due to daily moving averages, despite some bullish signals from weekly indicators, while monthly metrics indicate overall bearish sentiment.

As of March 2022, TELA Bio, Inc.'s management team includes Independent Chairman Mr. Douglas Evans, President and CEO Mr. Antony Koblish, and several Independent Directors: Mr. Kurt Azarbarzin, Mr. Vince Burgess, Ms. Lisa Colleran, Ms. Federica O'Brien, and Ms. Adele Oliva. This diverse team guides the company's governance and strategy.

TELA Bio, Inc. is a medical technology company that develops tissue reinforcement materials for soft tissue reconstruction. As of March 2025, it reported net sales of $19 million and a net loss of $11 million, with a market cap of $59.33 million.

As of Jun 18, TELA Bio, Inc. has a market capitalization of 59.33 million, with net sales of 71.22 million and a net profit of -43.44 million over the latest four quarters. Shareholder's funds are 28.46 million, and total assets amount to 87.33 million as of Dec 24.